Skip to main content
Erschienen in: World Journal of Surgery 2/2018

Open Access 10.10.2017 | Original Scientific Report

A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands

verfasst von: C. G. Genc, H. J. Klümpen, M. G. H. van Oijen, C. H. J. van Eijck, E. J. M. Nieveen van Dijkum

Erschienen in: World Journal of Surgery | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Large population-based studies give insight into the prognosis and treatment outcomes of patients with pancreatic neuroendocrine tumors (pNETs). Therefore, we provide an overview of the treatment and related survival of pNET in the Netherlands.

Methods

Patients diagnosed with pNET between 2008 and 2013 from the Netherlands Cancer Registry were included. Patient, tumors and treatment characteristics were reported. Survival analyses with log-rank testing were performed to compare survival.

Results

In total, 611 patients were included. Median follow-up was 25.7 months, and all-cause mortality was 42%. Higher tumor grade and TNM stage were significantly associated with worse survival in both the overall and metastasized population. The effect of distant metastases on survival was more significant in lower tumor stages (T1–3 p < 0.05, T4 p = 0.074). Resection of the primary tumor was performed in 255 (42%) patients. Patients who underwent surgery had the highest 5-year survival (86%) compared to PRRT (33%), chemotherapy (21%), targeted therapy and somatostatin analogs (24%) (all p < 0.001). Patients with T1M0 tumors (n = 115) showed favorable survival after surgical resection (N = 95) compared to no therapy (N = 20, p = 0.008). Resection also improved survival significantly in patients with metastases compared to other treatments (all p > 0.05). Without surgery, PRRT showed the best survival curves in patients with distant metastases. Grade 3 tumors and surgical resection were independently associated with survival (HR 7.23 and 0.12, respectively).

Conclusion

Surgical resection shows favorable outcome for all pNET tumors, including indolent tumors and tumors with distant metastases. Prospective trials should be initiated to confirm these results.
Literatur
1.
Zurück zum Zitat Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRefPubMed Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRefPubMed
2.
Zurück zum Zitat Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72CrossRefPubMed Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72CrossRefPubMed
3.
Zurück zum Zitat Modlin IM, Lye KD (2003) Kidd M A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959CrossRefPubMed Modlin IM, Lye KD (2003) Kidd M A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959CrossRefPubMed
5.
Zurück zum Zitat Kloppel G (2007) Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:15–31CrossRefPubMed Kloppel G (2007) Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:15–31CrossRefPubMed
6.
Zurück zum Zitat Casparie M, Tiebosch AT, Burger G et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19–24PubMedPubMedCentral Casparie M, Tiebosch AT, Burger G et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19–24PubMedPubMedCentral
8.
Zurück zum Zitat Goldbohm R, van der Brandt P, Dorant E (1994) Estimation of the coverage of Dutch municipalities by cancer registries and PALGA based on hospital discharge. TSG 72:80–84 Goldbohm R, van der Brandt P, Dorant E (1994) Estimation of the coverage of Dutch municipalities by cancer registries and PALGA based on hospital discharge. TSG 72:80–84
9.
Zurück zum Zitat Schouten LJ, Hoppener P, van den Brandt PA et al (1993) Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 22:369–376CrossRefPubMed Schouten LJ, Hoppener P, van den Brandt PA et al (1993) Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 22:369–376CrossRefPubMed
10.
Zurück zum Zitat Jensen OM, Storm HH (1991) Cancer registration: principles and methods. Reporting of results. IARC Sci Publ 95:108–125 Jensen OM, Storm HH (1991) Cancer registration: principles and methods. Reporting of results. IARC Sci Publ 95:108–125
11.
Zurück zum Zitat Fritz AG (2000) International classification of diseases for oncology: ICDO, 3rd edn. World Health Organization, Geneva Fritz AG (2000) International classification of diseases for oncology: ICDO, 3rd edn. World Health Organization, Geneva
12.
Zurück zum Zitat Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401CrossRefPubMedPubMedCentral Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103:153–171CrossRefPubMedPubMedCentral Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103:153–171CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Bar-Moshe Y, Mazeh H, Grozinsky-Glasberg S (2017) Non-functioning pancreatic neuroendocrine tumors: surgery or observation? World J Gastrointest Endosc 9:153–161CrossRefPubMedPubMedCentral Bar-Moshe Y, Mazeh H, Grozinsky-Glasberg S (2017) Non-functioning pancreatic neuroendocrine tumors: surgery or observation? World J Gastrointest Endosc 9:153–161CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Guo J, Zhao J, Bi X et al (2017) Should surgery be conducted for small nonfunctioning pancreatic neuroendocrine tumors: a systemic review. Oncotarget 8:35368–35375PubMedPubMedCentral Guo J, Zhao J, Bi X et al (2017) Should surgery be conducted for small nonfunctioning pancreatic neuroendocrine tumors: a systemic review. Oncotarget 8:35368–35375PubMedPubMedCentral
16.
Zurück zum Zitat Ricci C, Taffurelli G, Campana D et al (2017) Is surgery the best treatment for sporadic small (≤ 2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. Pancreatology 17:471–477CrossRefPubMed Ricci C, Taffurelli G, Campana D et al (2017) Is surgery the best treatment for sporadic small (≤ 2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. Pancreatology 17:471–477CrossRefPubMed
17.
Zurück zum Zitat Fairweather M, Swanson R, Wang J et al (2017) Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol 24:2319–2325CrossRefPubMed Fairweather M, Swanson R, Wang J et al (2017) Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol 24:2319–2325CrossRefPubMed
18.
Zurück zum Zitat Citterio D, Pusceddu S, Facciorusso A et al (2017) Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. Eur J Surg Oncol 43:380–387CrossRefPubMed Citterio D, Pusceddu S, Facciorusso A et al (2017) Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. Eur J Surg Oncol 43:380–387CrossRefPubMed
19.
Zurück zum Zitat Almond LM, Hodson J, Ford SJ et al (2017) Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: a systematic review and meta-analysis. Eur J Surg Oncol. doi:10.1016/j.ejso.2017.05.016 Almond LM, Hodson J, Ford SJ et al (2017) Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: a systematic review and meta-analysis. Eur J Surg Oncol. doi:10.​1016/​j.​ejso.​2017.​05.​016
20.
Zurück zum Zitat Partelli S, Inama M, Rinke A et al (2015) Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. Neuroendocrinology 102:68–76CrossRefPubMed Partelli S, Inama M, Rinke A et al (2015) Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. Neuroendocrinology 102:68–76CrossRefPubMed
21.
Zurück zum Zitat Halfdanarson TR, Rabe KG, Rubin J et al (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733CrossRefPubMedPubMedCentral Halfdanarson TR, Rabe KG, Rubin J et al (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733CrossRefPubMedPubMedCentral
Metadaten
Titel
A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands
verfasst von
C. G. Genc
H. J. Klümpen
M. G. H. van Oijen
C. H. J. van Eijck
E. J. M. Nieveen van Dijkum
Publikationsdatum
10.10.2017
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 2/2018
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4278-y

Weitere Artikel der Ausgabe 2/2018

World Journal of Surgery 2/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.